ArticleFrontiers in oncology2024

Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type.

Roberto Buonaiuto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.